Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026)

Neurocrine Biosciences has reported Net Cash Flow for 17 years, with the latest figure at -$446.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1047.81% year-over-year to -$446.5 million; the trailing twelve-month figure through Mar 2026 stood at $72.4 million (up 135.81% YoY), and the FY2025 full-year result was $480.0 million, up 2751.93% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$446.5 million, down from $372.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $372.8 million in Q4 2025, with the low at -$446.5 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$4.0 million across 5 years, with a median of $48.9 million in 2022.
• Annual changes were most pronounced in 2025 — Net Cash Flow soared 421.93% — and 2026, when it plunged 1047.81%.
• Neurocrine Biosciences' Net Cash Flow stood at $52.0 million in 2022, then sank by 182.5% to -$42.9 million in 2023, then slumped by 169.93% to -$115.8 million in 2024, then soared by 421.93% to $372.8 million in 2025, then plunged by 219.77% to -$446.5 million in 2026.
• The last three Net Cash Flow figures came in at -$446.5 million (Q1 2026), $372.8 million (Q4 2025), and $76.4 million (Q3 2025), per Business Quant data.